Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

被引：0
|
作者：
Chang, Darryl [1 ,2 ]
Habib, Alma [2 ,3 ]
Uegel, Andrew [2 ,4 ]
Struble, Emily [2 ,4 ]
Shaikh, Hira [2 ,4 ]
Strouse, Christopher [2 ,4 ]
Green, Kimberly M. [2 ,5 ]
Mushtaq, Muhammad Umair [2 ,6 ]
Mahmoudjafari, Zahra [2 ,6 ]
Hashmi, Hamza [2 ,7 ]
Mcguirk, Joseph P. [2 ,8 ]
Khan, Abdullah Mohammad [2 ,3 ]
Abdallah, Al-Ola [2 ,8 ]
Ahmed, Nausheen [2 ,6 ]
Atrash, Shebli [1 ,2 ]
Bhutani, Manisha [1 ,2 ]
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[3] Ohio State Univ, Div Hematol, Columbus, OH USA
[4] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa, LA USA
[5] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA
[6] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
[8] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208692
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2404 / 2405
页数：2
相关论文
共 50 条
  • [31] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
  • [32] Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
    Logue, Jennifer M.
    Peres, Lauren C.
    Hashmi, Hamza
    Colin-Leitzinger, Christelle M.
    Shrewsbury, Alexandria M.
    Hosoya, Hitomi
    Gonzalez, Rebecca M.
    Copponex, Christina
    Kottra, Krista H.
    Hovanky, Vanna
    Sahaf, Bita
    Patil, Sunita
    Lazaryan, Aleksandr
    Jain, Michael D.
    Baluch, Aliyah
    Klinkova, Olga V.
    Bejanyan, Nelli
    Faramand, Rawan G.
    Elmariah, Hany
    Khimani, Farhad
    Davila, Marco L.
    Mishra, Asmita
    Blue, Brandon J.
    Grajales-Cruz, Ariel F.
    Puglianini, Omar A. Castaneda
    Liu, Hien D.
    Nishihori, Taiga
    Freeman, Ciara L.
    Brayer, Jason B.
    Shain, Kenneth H.
    Baz, Rachid C.
    Locke, Frederick L.
    Alsina, Melissa
    Sidana, Surbhi
    Hansen, Doris K.
    BLOOD ADVANCES, 2022, 6 (24) : 6109 - 6119
  • [33] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Imanak, Ken
    Lee, Abraham
    Campbell, Timothy B.
    Patwardhan, Pallavi
    ADVANCES IN THERAPY, 2023, 40 (10) : 4626 - 4638
  • [34] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    November McGarvey
    Brian Ung
    Thomas Carattini
    Ken Imanak
    Abraham Lee
    Timothy B. Campbell
    Pallavi Patwardhan
    Advances in Therapy, 2023, 40 : 4626 - 4638
  • [35] Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Berdeja, Jesus G.
    De Stefano, Valerio
    Gay, Francesca
    Hooper, Becky
    Haltner, Anja
    Kumar, Shaji
    Martin, Thomas
    Mateos, Maria-Victoria
    Moreau, Philippe
    Rosta, Emily
    Samjoo, Imtiaz A.
    Usmani, Saad Z.
    Weisel, Katja
    Jackson, Carolyn C.
    Olyslager, Yunsi
    Schecter, Jordan M.
    Vogel, Martin
    Garrett, Ashraf
    Lee, Sam
    Nesheiwat, Tonia
    Pacaud, Lida
    Zhou, Changwei
    Valluri, Satish
    Costa, Luciano J.
    Lin, Yi
    BLOOD, 2021, 138
  • [36] Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
    Parrondo, Ricardo D.
    Sam, Keren
    Rasheed, Ahsan
    Alegria, Victoria
    Sher, Taimur
    Roy, Vivek
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [37] Outcomes of Outpatient Administration of Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Refractory Multiple Myeloma (RRMM)
    Gregory, Tara
    De Braganca, Kevin C.
    Alegria, Victoria
    Perciavalle, Matthew
    Ranjan, Sandip
    Mothe, Raj Kumar
    Bixby, Todd
    Qureshi, Zaina P.
    BLOOD, 2024, 144 : 7591 - 7592
  • [38] MINIMAL RESIDUAL DISEASE NEGATIVITY AS A MEASURE OF RESPONSE TO CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Aronson, Elizabeth
    Madduri, Deepu
    Suarez, Jacklyn
    Florendo, Erika
    Pacaud, Lida
    Steinbach, Mary
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [39] Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
    Wu, Liviawati S.
    Su, Yaming
    Li, Claire
    Zhou, Wangda
    Jackson, Carolyn C.
    Sun, Yu-Nien
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (12): : 3000 - 3011
  • [40] Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
    Trando, Aaron
    Ghamsari, Farid
    Yeung, Philip
    Costello, Caitlin
    Saunders, Ila
    Jeong, Ah-Reum
    BIOMEDICINES, 2025, 13 (01)
12345